Trial Profile
A Phase 1b, Open-Label, Dose-Escalation Study for the Safety, Tolerability, and Pharmacokinetics of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Parsaclisib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions
- Acronyms CITADEL-111
- Sponsors Incyte Corporation
- 09 Aug 2023 Status changed from active, no longer recruiting to completed.
- 28 Jul 2022 Planned End Date changed from 30 Jun 2023 to 31 Mar 2023.
- 01 May 2022 Results published in the Cancer Science